Regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting β2-agonist; patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.